Top Tweets for #clonevo
#CLONEVO study: Targeting cyclin D1 amplifications in #BladderCancer with abemaciclib. @FaltasLab @WeillCornell joins @zklaassen_md @GACancerCenter to discuss this window-of-opportunity trial evaluating abemaciclib, a CDK4/6 inhibitor, in cisplatin-ineligible muscle-invasive bladder cancer #MIBC. #WatchNow > https://t.co/HT6TcDNo0Q
#CLONEVO study: Targeting cyclin D1 amplifications in #BladderCancer with abemaciclib. @FaltasLab @WeillCornell joins @zklaassen_md @GACancerCenter to discuss this window-of-opportunity trial evaluating abemaciclib, a CDK4/6 inhibitor, in cisplatin-ineligible muscle-invasive bladder cancer #MIBC. #WatchNow > https://t.co/HT6TcDNo0Q
#CLONEVO study: Targeting cyclin D1 amplifications in #BladderCancer with abemaciclib. @FaltasLab @WeillCornell joins @zklaassen_md @GACancerCenter to discuss this window-of-opportunity trial evaluating abemaciclib, a CDK4/6 inhibitor, in cisplatin-ineligible muscle-invasive bladder cancer #MIBC. #WatchNow > https://t.co/HT6TcDNo0Q
#CLONEVO study: Targeting cyclin D1 amplifications in #BladderCancer with abemaciclib. @FaltasLab @WeillCornell joins @zklaassen_md @GACancerCenter to discuss this window-of-opportunity trial evaluating abemaciclib, a CDK4/6 inhibitor, in cisplatin-ineligible muscle-invasive bladder cancer #MIBC. #WatchNow > https://t.co/HT6TcDNo0Q
Enjoyed my conversation with @zklaassen_md @urotoday to discuss #CLONEVO, our window-of-opportunity trial evaluating abemaciclib, a CDK4/6 inhibitor, in cisplatin-ineligible muscle-invasive #bladdercancer @WCMGUcancer @WeillCornell
#CLONEVO study: Targeting cyclin D1 amplifications in #BladderCancer with abemaciclib. @FaltasLab @WeillCornell joins @zklaassen_md @GACancerCenter to discuss this window-of-opportunity trial evaluating abemaciclib, a CDK4/6 inhibitor, in cisplatin-ineligible muscle-invasive bladder cancer #MIBC. #WatchNow > https://t.co/HT6TcDNo0Q
#CLONEVO study: Targeting cyclin D1 amplifications in #BladderCancer with abemaciclib. @FaltasLab @WeillCornell joins @zklaassen_md @GACancerCenter to discuss this window-of-opportunity trial evaluating abemaciclib, a CDK4/6 inhibitor, in cisplatin-ineligible muscle-invasive bladder cancer #MIBC. #WatchNow > https://t.co/HT6TcDNo0Q
🔎 @FaltasLab gives an overview of the #CLONEVO study, which is the first window-of-opportunity trial of a CDK4/6 inhibitor—abemaciclib—in muscle-invasive #bladdercancer: https://t.co/fWgX5xJ8Yb
🗣️Bladder Rapid Oral Abstracts #ASCO25
👉Abs4520: Dr @FaltasLab presenting #abemaciclib cis-ineligible MIBC on #CLONEVO
🩺Clinical implications:
- Preoperative #abemaciclib in MIBC demonstrated promising efficacy and tolerability while modulating cell cycle-dependent pathways
- Consider future studies in combination with ADCs (EV/P)
-------------------------------------------------------
n = 20 (16/20 males)
5/20 cT4.
3 didn't undergo RC, 1 withdrew consent.
💉abema (200mg BID PO) x 4-8 weeks prior to RC
✅ pCR = 18.8% (3/16)
✅ downstaging = 31.3% (5/16)
⚠️G3 TRAE anemia (4/20), abdominal pain (1/20) and diarrhea (1/20)
🩻 Imaging Mass Cytometry of pre/post 👇 RB1 phosphorylation
🧬 VAF 👇after abema by 20.5% (p = 0.04)
🧬 ctDNA tumor fraction(TF)👇after abema by 28.6%
⭐️Pt w/ CCND1 amplification most significant decrease in TF (63.8%) highlighting CCND1 as a potential response biomarker
👥@DrRosenbergMSK @MichvdHeijden @FaltasLab @SuzanneColeMD @cnsternberg @MattGalsky @bergsa83 @alantanmd @tompowles1 @DrKarieRuncie @BraunMDPhD @PGrivasMDPhD @shilpaonc @AmandaNizamMD @DrKarineTawagi @DrYukselUrun @ReneeSaliby @drenriquegrande @bavilima @DRBakaloudiMD @ReginaBarCar @crisbergerot @kidneycan @KidneyCancer @ASCO @OncoAlert @OncBrothers @OncLive @BladderCancerUS
Excited to see these outstanding presentations advancing care for patients with genitourinary malignancies! Thank you @OncoAlert for highlighting our #CLONEVO investigator-initiated trial https://t.co/opOXhj0Z5Y See you tomorrow! 🏢 at the Arie Crown Theater at 2.15 PM 🕐 #ASCO25 @ASCO
The #ASCO25 #OncoAlertTOP10 Abstracts in #GUOncology These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸
#ProstateCancer #BladderCancer #kidneyCancer
⭐Abs 4518 SURE-02: NEOADJUVANT SACITUZUMAB GOVITECAN PLUS PEMBROLIZUMAB, FOLLOWED BY RESPONSE-ADAPTED BLADDER SPARING AND ADJUVANT PEMBRO, IN MUSCLE-INVASIVE BLADDER CANCER
⭐Abs 4521 AREN1721: AXITINIB+NIVOLUMAB COMBINATION THERAPY VS. SINGLE AGENT NIVOLUMAB FOR THE TREATMENT OF TFE/TRANSLOCATION RENAL CELL CARCINOMA ACROSS ALL AGE GROUPS
⭐Abs 5000 CAN-2409+PRODRUG IN COMBINATION WITH STANDARD OF CARE EXTERNAL BEAM RADIATION (EBRT) FOR NEWLY DIAGNOSED LOCALIZED PROSTATE CANCER
⭐Abs LBA5006 SUNRISE-4: TAR-200 + CETRELIMAB OR CET ALONE AS NEOADJUVANT THERAPY IN MUSCLE-INVASIVE BLADDER CANCER INELIGIBLE FOR OR REFUSE NEOADJUVANT CISPLATIN-BASED CHEMOTHERAPY
⭐Abs 5019 TALAPRO-2: HOMOLOGOUS RECOMBINATION REPAIR ALTERATIONS BY GENE SUBGROUP AND POTENTIAL ASSOCIATIONS WITH EFFICACY IN THE HRR-DEFICIENT POPULATION
⭐Abs 4500 CHECKMATE 901 PHASE 3 TRIAL: IPI/NIVO VS GEM/CARBO AS 1L THERAPY IN CISPLATIN-INELIGIBLE
PATIENTS WITH MUC
⭐Abs 4514 FIVE-YEAR FOLLOW-UP KEYNOTE-564 STUDY OF ADJUVANT PEMBROLIZUMAB (PEMBRO)
FOR THE TREATMENT OF CLEAR CELL RENAL CELL CARCINOMA
⭐Abs 4516 PDIGREE (ALLIANCE A031704): IPILIMUMAB AND NIVOLUMAB IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA (MCCRCC)
⭐Abs 4517
CREST: SASANLIMAB IN COMBINATION WITH BACILLUS CALMETTE-GUÉRIN (BCG) IN BCG-NAIVE, HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): EVENT-FREE SURVIVAL (EFS)
⭐Abs 4506 COMBINATION CASDATIFAN PLUS CABOZANTINIB EXPANSION COHORT OF PHASE 1 ARC-20
STUDY IN PREVIOUSLY TREATED PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA
⭐Abs LBA4513 ENLIGHTED INTERIM RESULTS OF EFFICACY AND SAFETY OF PADELIPORFIN VASCULAR TARGETED PHOTODYNAMIC THERAPY IN TREATMENT OF LOW-GRADE UPPER TRACT UROTHELIAL CANCER
⭐Abs 4520 CLONEVO: PREOPERATIVE ABEMACICLIB FOR CISPLATIN-INELIGIBLE MUSCLE-INVASIVE BLADDER CANCER (MIBC) WITH MOLECULAR RESPONSE ASSESSMENT
⭐Abs LBA5012 AN OPEN LABEL RANDOMIZED NON-INFERIORITY TRIAL COMPARING ADJUVANT PLATINUM PLUS PACLITAXEL TO PLATINUM PLUS 5-FU AFTER CURATIVE RESECTION IN HIGH-RISK PENILE CARCINOMA
Lead @nataliagandur @ReginaBarCar @yekeduz_emre @weoncologists
Faculty: @apolo_andrea @DrChoueiri @PGrivasMDPhD @ravikanesvaran @neerajaiims @amerseburger @drenriquegrande @Silke_Gillessen
Ping GU Faculty
@montypal @crisbergerot @DrDanielHeng @DrChoueiri @TiansterZhang @HHammersMD @sonpavde @drenriquegrande @scserendipity1
@EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas
@DrYukselUrun
#OncoAlertAF
@acampsmalea @BRicciutiMD
@HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
#ASCO25 #CLONEVO Preoperative Abemaciclib for Cisplatin Ineligible #MIBC with Molecular Response Assessment - Results from CLONEVO — the first trial of pre-op abemaciclib in cisplatin-ineligible MIBC. The CDK4/6 inhibitor showed promising pathologic responses and on-target molecular effects, including E2F pathway suppression and tumor burden reduction via ctDNA. A potential path forward for biomarker-driven therapy. #BladderCancer #UroOnc #PrecisionMedicine > https://t.co/8YO1uML1AG @FaltasLab @zklaassen_md @EliLillyandCo @DrScottTagawa @cnsternberg @DrJonesNauseef @ASCO
Beyond excited to present the results of our investigator-initiated #CLONEVO trial at #ASCO25 @ASCO! 🏢Arie Crown Theater on May 31, 2025 🕐
Only 4 weeks of pre-op abemaciclib in patients with cisplatin-ineligible MIBC resulted in:
✅ 31% pathologic downstaging
✅ Clear on-target activity through ⬇️ Rb phosphorylation & Ki67. Measured by spatial immune mass cytometry in more than 630,000 single cells from matched pre-/post-abemaciclib tissues 🔬
🩸🧪 Serial ctDNA analysis shows tumor fraction reduction was driven by abema, not TURBT
☑️Tumors with CCND1 ⭕️ amplification are more likely to respond (very cool underlying biology!)
⬇️ decreased expression of critical DNA damage proteins TOBP1 and RAD51. Providing rationale for testing sequencing CDK4/6 inhibitors after DNA-damaging therapies, including ADCs, to inhibit cancer cells from repairing double-strand DNA breaks
https://t.co/omrwyHhKJd
@MHosmanMD @cnsternberg @DoctorMargolis @DrJonesNauseef @DrAnaMolina @DrDavidNanus @rohitjainMD @scientistatlrge @DrMhidalgo @notSoJunkDNA @willbfx @ElementoLab @SuzanneColeMD @DrScottTagawa #clinicaltrials #teamscience
4.#CLONEVO: Preoperative abemaciclib for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) with molecular response assessment. Abema resulted in pathologic complete response in 18.8% (3/16) and downstaging in 31.3% (5/16).
Stellar neoadjuvant/adjuvant clinical trials session today #AACR25 @AACR chaired by @aparna1024! @FaltasLab presented #CLONEVO trial, neoadjuvant abemaciclib for cis-ineligible #bladdercancer - we participated @utswcancer led by @SuzanneColeMD!
Progress in #BladderCancer research. @FaltasLab @EngIPM joins @CaPsurvivorship @NUFeinbergMed to discuss the cutting edge aspects of his research on #urothelial #cancer and the #CLONEVO trial. #WatchNow on UroToday > https://t.co/9f57l3JOOV @WeillCornell
Progress in #BladderCancer research. @FaltasLab @EngIPM joins @CaPsurvivorship @NUFeinbergMed to discuss the cutting edge aspects of his research on #urothelial #cancer and the #CLONEVO trial. #WatchNow on UroToday > https://t.co/9f57l3sdql @WeillCornell
Last Seen Hashtags on Sotwe
ทอมนัดเย็ด
Seen from Thailand
mallupoori
Seen from India
사디스트
Seen from United States
turkgay
Seen from Turkey
arrimonesconsensuados
Seen from United States
monkeyapp
Seen from United Kingdom
antalyacd
Seen from Turkey
입던팬티
Seen from Korea
pang3pong
Seen from Thailand
nolimits()*************
Seen from United States
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.9M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.3M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.5M followers
KATY PERRY
@katyperry
89M followers
Taylor Swift
@taylorswift13
82.9M followers
Lady Gaga
@ladygaga
74.4M followers
Virat Kohli
@imvkohli
71.9M followers
Kim Kardashian
@kimkardashian
70.5M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.9M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62.1M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers